In vitro: In the presence of G-CSF, AM580 (at 10-8 M) produces a remarkable induction in LAP mRNA of NB4 cells. At a concentration of 10-5 M, AM580 and ATRA, in combination with G-CSF, induce almost the same level of LAP transcript. AM580 (at 10-8 M) leads to an approximately sixfold increase in the steady-state levels of the transcript coding for the G-CSF receptor in NB4 cells. AM580 (50 nM) increases caspase-3 expression in all of the colonies, and in 30% of the colonies induce acinar-like cavitation. Knockdown of RARγ1 in primary Myc cells using shRARγ1 followed by Am580 treatment results in an even higher level of CRBP1 expression, showing that in these cells RARγ has a repressive effect on the RARα target gene CRBP1. Am580 (200 nM) enhances the anti-proliferative effect exhibited by RARγ knockdown in the MCF-10A and MCF-7 cell lines but not in the MDA-MB-231 cells.
In vivo: Am580 (0.3 mg/kg/day) treatment has a more profound effect on tumor-free survival of MMTV-wnt1 mice, the effect being noticeable even in early appearing tumors, and no overt toxicity is found in liver, lungs, kidney, and spleen. Am580 treatment reduces substantially and equally the level of hyperplasia in both transgenic glands. Treatment of MMTV-Myc mice with the RARα-selective agonist Am580 leads to significant inhibition of mammary tumor growth, lung metastasis and extends tumor latency in 63% of mice.
|Cell lines||Leukemic cells|
|Preparation method||Leukemic cells were incubated with various concentrations of JY-1-106 (2–20 μM) alone or with DMSO (as a vehicle) at different time point in 96-well plates. Cells treated with SR11253 200 nM, Am580 200 nM and RA 1 μM individually or together with JY-1-106 (12 μM) for 48 h.|
|Incubation time||48 h|
|Solubility (25°C)||45 mg/mL in DMSO|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related RAR/RXR Products|
Trifarotene (CD5789) is a potent and selective RARγ agonist. Trifarotene (CD5789) shows ∼65-fold and ∼16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM), respectively.
9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities.
AGN194204 (IRX4204) is inactive against RAR and is an orally active and selective RXR agonist with Kd values of 0.4 nM, 3.6 nM and 3.8 nM for RXRα, RXRβ and RXRγ, respectively, and EC50s of 0.2 nM, 0.8 nM and 0.08 nM. AGN194204 has anti-inflammatory and anti-cancer effects.
9-cis-Retinoic acid (ALRT1057), a derivative of vitamin A, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates the cell cycle and has anticancer, anti-inflammatory and neuroprotective activities.
Vitamin A (Retinol) is a naturally occuring fat-soluble vitamin that is important for normal vision, the immune system, and reproduction. It also plays roles in normal functioning of heart, lungs, kidneys, and other organs.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.